Aromasin "Suicide Inhibition" May Distinguish Drug From Other Inhibitors
Aromasin's labeled "suicide inhibition" mechanism of action could be used by Pharmacia & Upjohn to distinguish the new drug, approved Oct. 21, from nonsteroidal aromatase inhibitors in the treatment of breast cancer.
You may also be interested in...
Searle will create a platform for new oncologics development through a research collaboration with Cambridge Antibody Technology.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011